Abstract 72P
Background
Group 3 Medulloblastoma (MB) is a subgroup of MB with poor prognosis and high chances of recurrence. The highly aggressive nature of this paediatric brain tumor necessitates targeted therapeutic approaches to improve patient outcomes. Phosphoenolpyruvate carboxykinase plays a crucial role in gluconeogenesis by catalyzing the conversion of oxaloacetate to phosphoenolpyruvate. PCK2 is the mitochondrial counterpart of this enzyme, helping in replenishment of various metabolic intermediates and hence acting as a pivotal protein between pyruvate metabolism, TCA cycle and gluconeogenesis. Recent proteomic studies on Medulloblastoma (MB) suggest extensive metabolic rewiring in Group 3 MB.
Methods
Analysis of publicly available omics data on Medulloblastoma was performed to identify the expression levels of proteins related to key metabolic pathways like Krebs cycle, pyruvate metabolism and glucose metabolism including PCK2. Key proteins belonging to these pathways were analysed in FFPE tissues from MB patients and compared with other subgroups using multiple reaction monitoring. PCK2 was knocked down in Group 3 cell lines using shRNA and evaluated for effects on proliferation and survival using culture based in vitro assays. High resolution label free proteomic analysis was performed to ascertain the effects of PCK2 knockdown.
Results
Data mining and repository data analysis found dysregulation of key proteins and metabolites. Key proteins involved in energy metabolism including PCK2 showed upregulation even at the transcriptomic level. Proteomic analysis on few FFPE samples could validate these findings. shRNA based PCK2 knockdown resulted in lowering the proliferation rates of Group 3 cells and significant changes in their proteomes.
Conclusions
The overexpression of PCK2 is involved in the aggressiveness of Group 3 MB and can be a possible target for this subset of medulloblastoma patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract